List of Excipients in Branded Drug REXALL ANTI DIARRHEAL

« Back to Dashboard

Generic Drugs Containing REXALL ANTI DIARRHEAL

Company	Ingredient	NDC	Excipient
Dolgencorp LLC	loperamide hydrochloride	55910-700	ANHYDROUS LACTOSE
Dolgencorp LLC	loperamide hydrochloride	55910-700	CARNAUBA WAX
Dolgencorp LLC	loperamide hydrochloride	55910-700	CELLULOSE, MICROCRYSTALLINE
Dolgencorp LLC	loperamide hydrochloride	55910-700	D&C YELLOW NO. 10
Dolgencorp LLC	loperamide hydrochloride	55910-700	FD&C BLUE NO. 1
Dolgencorp LLC	loperamide hydrochloride	55910-700	HYPROMELLOSES

What are the Most Frequently-Used Excipients in REXALL ANTI DIARRHEAL?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CARNAUBA WAX
1	CELLULOSE, MICROCRYSTALLINE
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
1	HYPROMELLOSES

Rexall Anti-Diarrheal Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Rexall Anti-Diarrheal is generally positioned as an over-the-counter loperamide hydrochloride product, typically supplied as a 2 mg tablet, caplet, or softgel. Its commercial opportunity is driven by low-cost manufacturing, rapid disintegration, swallowability, packaging compliance, and retailer differentiation rather than active-ingredient exclusivity. The strongest excipient strategy is a simple, robust immediate-release formulation that supports low unit cost, stable shelf life, and clear abuse-deterrence messaging.

Product-specific excipients can differ by Rexall stock-keeping unit, dosage form, manufacturer, and market. The analysis below applies to the standard loperamide hydrochloride 2 mg oral product sold under the Rexall brand.

What is Rexall Anti-Diarrheal and what active ingredient does it contain?

Rexall Anti-Diarrheal is an OTC gastrointestinal product generally based on loperamide hydrochloride, an opioid-receptor agonist that acts primarily in the intestinal tract to reduce gastrointestinal motility. Standard OTC products contain 2 mg of loperamide hydrochloride per dosage unit.[1]

Product attribute	Typical Rexall Anti-Diarrheal profile
Active ingredient	Loperamide hydrochloride
Typical strength	2 mg per tablet, caplet, or softgel
Therapeutic category	OTC antidiarrheal
Primary use	Relief of acute nonspecific diarrhea
Regulatory pathway	OTC monograph or monograph-aligned product, depending on jurisdiction
Prescription status	Generally nonprescription at approved doses
Primary competitors	Imodium, store-brand loperamide, generic loperamide
Main commercial differentiators	Price, dosage form, count, packaging, retailer availability, brand trust

The product is a mature genericized medicine. Its excipient platform must therefore support operational advantages rather than provide basic market access.

What excipients are commonly used in Rexall Anti-Diarrheal formulations?

Typical loperamide tablets use standard solid-dose excipients selected for manufacturability and immediate release. Common categories include fillers, binders, disintegrants, glidants, lubricants, coating agents, and colorants.

Excipient category	Common examples	Commercial function
Diluent or filler	Microcrystalline cellulose, lactose, dibasic calcium phosphate, starch	Provides tablet mass and compressibility
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Promotes tablet breakup after swallowing
Lubricant	Magnesium stearate, stearic acid	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Improves appearance, handling, taste, and identification
Sweetener or flavor	Sucralose, mannitol, flavor systems	Supports chewable or orally disintegrating formats
Softgel vehicle	Polyethylene glycol, glycerin, gelatin, purified water	Supports liquid-fill capsule manufacture

The exact inactive-ingredient list should be confirmed against the applicable Rexall package label and regulatory database before making a formulation, labeling, or equivalence determination. FDA’s Inactive Ingredient Database is useful for assessing prior use by route and dosage form.[2]

How should the excipient strategy be optimized for loperamide tablets?

The preferred baseline is a conventional immediate-release tablet using a low-cost, widely qualified excipient system. The formulation should prioritize content uniformity, low friability, rapid disintegration, and reliable dissolution.

Recommended baseline formulation architecture

A practical platform could use microcrystalline cellulose or dibasic calcium phosphate as the principal filler, croscarmellose sodium or crospovidone as the disintegrant, povidone or pregelatinized starch as the binder, colloidal silicon dioxide as the glidant, and magnesium stearate as the lubricant.

The main development risks are not usually active-ingredient solubility alone. They include:

• Over-lubrication, which can slow dissolution.
• Excessive tablet hardness, which can delay disintegration.
• Poor powder flow at the low 2 mg drug load.
• Segregation of loperamide during blending.
• Inconsistent color or coating performance.
• Moisture-related stability changes.
• Sticking during compression or coating.

Because the active ingredient represents a small fraction of tablet mass, blend uniformity is a critical process-control issue. Geometric dilution, ordered blending, granulation, or a validated low-shear mixing sequence may be needed depending on particle size and bulk density.

Excipient selection priorities

A commercial formulation should use excipients with:

1. Multiple qualified suppliers.
2. Established compendial status.
3. Reliable global availability.
4. Low risk of nitrosamine or elemental-impurity concerns.
5. Compatibility with direct compression or simple wet granulation.
6. Low sensitivity to humidity.
7. Existing regulatory precedent in oral immediate-release products.

A lactose-free option can support broader consumer positioning, but it may increase cost or reduce compression efficiency if replaced with premium polyols or specialty fillers. A starch- and gluten-positioning strategy may also require careful substantiation because excipient origin and cross-contamination controls vary by supplier.

What formulation opportunities exist beyond the standard tablet?

The principal commercial opportunities are dosage-form upgrades and consumer-use improvements. They must be balanced against the low selling price of generic loperamide.

Softgel capsules

Softgels offer a smooth swallowing experience and can provide a premium alternative to standard tablets. Polyethylene glycol-based fills may support a compact dosage form, but the platform introduces higher manufacturing costs, gelatin-shell considerations, moisture migration, and greater packaging sensitivity.

Softgels may be attractive for:

• Premium private-label products.
• Travel-oriented diarrhea relief.
• Consumers who have difficulty swallowing tablets.
• Combination products with electrolytes or probiotics, subject to regulatory review.

Chewable tablets

Chewables can improve administration for consumers who do not want to swallow tablets. Taste masking is the main technical barrier because loperamide can produce an unpleasant sensory profile. Suitable approaches include polymeric taste-masking systems, ion-exchange resins, coated drug particles, and intensive sweetener-flavor systems.

The product must preserve dosing accuracy and avoid encouraging use beyond labeled directions. Excessively appealing flavoring may be commercially attractive but can create packaging and misuse concerns.

Orally disintegrating tablets

An orally disintegrating tablet could differentiate the product through water-free administration. The formulation would require rapid disintegration, acceptable mouthfeel, low friability, and effective taste masking.

Potential excipient systems include mannitol, crospovidone, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and polymeric taste-masking agents. The main risks are moisture sensitivity, tablet fragility, and higher packaging costs.

Liquid and pediatric-style formats

A liquid loperamide product presents a higher regulatory and safety burden. Accurate dosing, child-resistant packaging, taste masking, and age-specific labeling are essential. Loperamide products are subject to important pediatric safety restrictions, and product positioning should not imply suitability for children unless specifically authorized by the applicable label.[1][3]

What FDA regulatory status applies to Rexall Anti-Diarrheal?

Loperamide is an established OTC active ingredient. FDA’s OTC monograph framework identifies the conditions under which antidiarrheal products can be marketed without an individual new drug application, subject to compliance with active-ingredient, labeling, dosage, and manufacturing requirements.[1]

The commercial implications are significant:

• The product does not rely on new chemical-entity exclusivity.
• Excipient changes generally require pharmaceutical development and regulatory assessment rather than a new active-ingredient patent strategy.
• Label claims must remain consistent with the authorized OTC framework.
• Dosage-form changes may trigger additional product-specific regulatory work.
• Bioequivalence or comparative performance may be relevant when changing the dosage form or release profile.

Rexall-branded products may be manufactured by a contract manufacturer and marketed under private-label arrangements. The responsible labeler, NDC holder, and manufacturing site should be evaluated separately from the retail brand.

What is the Orange Book status of Rexall Anti-Diarrheal?

A standard OTC loperamide product is generally not protected by an Orange Book patent estate comparable to a prescription drug. The Orange Book primarily concerns approved prescription and certain approved nonprescription drug applications. A retailer’s OTC loperamide product may not have a meaningful product-specific Orange Book listing or patent-based exclusivity position.[4]

Patent and exclusivity profile

Category	Commercial assessment
Active ingredient	Mature, broadly genericized
Compound patent	No meaningful current barrier expected
Standard tablet formulation	Low patent differentiation
Method-of-use patents	Limited practical relevance for ordinary OTC claims
Excipient patents	Possible but unlikely to block ordinary generic products
Orange Book leverage	Generally limited for a conventional OTC product
Regulatory exclusivity	Generally not the principal commercial barrier
Manufacturing know-how	Potentially more valuable than patent rights

The most defensible intellectual-property opportunities would involve a distinct formulation or delivery system, such as a rapidly dispersing tablet, taste-masked multiparticulate system, abuse-resistant configuration, or combination product. Even these rights would need to demonstrate meaningful technical performance and commercial differentiation.

When does Rexall Anti-Diarrheal lose exclusivity?

Rexall Anti-Diarrheal is generally a mature OTC product without a material remaining exclusivity period based on the loperamide molecule. Generic entry is already established. Competitive protection depends on retailer placement, procurement economics, packaging, quality performance, and consumer recognition.

A new Rexall formulation could create limited product-specific protection through:

• A formulation patent.
• A design patent for packaging or device components.
• Trade dress.
• Confidential manufacturing parameters.
• Supplier exclusivity.
• Contractual private-label arrangements.

These mechanisms would not prevent substitution by conventional loperamide tablets unless the protected feature is necessary for a legally equivalent product.

What generic entry risks exist for Rexall Anti-Diarrheal?

Generic and private-label entry risk is high because the product has a low technical barrier and many alternative suppliers. The principal competitors include national-brand loperamide, pharmacy private labels, mass-retail products, dollar-store products, and online generic sellers.

Risk factor	Exposure
Active-ingredient substitution	Very high
Conventional tablet competition	Very high
Softgel competition	High
Retail price compression	High
Supply interruption	Moderate to high
Formulation copying	High for ordinary tablets
Brand switching	High
Regulatory change	Moderate
Packaging differentiation	Moderate

A conventional product can be copied through established generic manufacturing routes. The strongest defenses are supply reliability, low landed cost, low complaint rates, effective retailer service levels, and differentiated pack sizes.

Which excipient innovations have the strongest commercial potential?

The most credible opportunities are those that solve a consumer or manufacturing problem without materially increasing cost.

High-potential opportunities

• A lactose-free, low-cost immediate-release tablet.
• A compact caplet with improved swallowability.
• A moisture-resistant tablet for hot and humid markets.
• A taste-masked chewable product.
• A rapidly disintegrating tablet packaged in unit-dose blister packs.
• A color-coded product family for adult, travel, and combination gastrointestinal products.
• A formulation compatible with high-speed direct compression.
• A tablet with improved resistance to chipping and abrasion during automated retail handling.

Lower-potential opportunities

• Premium excipients with no measurable consumer benefit.
• Complex modified-release systems for an acute-use product.
• High-cost natural or “clean-label” excipients without an approved claim strategy.
• Probiotic combinations that complicate stability and regulatory positioning.
• Liquid products lacking a clear dosing advantage.

An acute antidiarrheal generally benefits from rapid and predictable release. Modified-release technology is unlikely to produce a strong value proposition unless supported by specific clinical or consumer evidence.

How does Rexall Anti-Diarrheal compare with Imodium and other loperamide products?

The active ingredient and standard dose are usually the same across conventional products. Differences arise mainly from dosage form, excipient composition, packaging, price, and distribution.

Attribute	Rexall Anti-Diarrheal	Imodium	Generic pharmacy product
Active ingredient	Typically loperamide HCl	Loperamide HCl	Loperamide HCl
Standard strength	2 mg	2 mg	2 mg
Brand position	Retail private label	National brand	Store or generic label
Price	Usually lower	Usually higher	Low to moderate
Excipient differentiation	Usually limited	Product-specific	Usually limited
Consumer trust	Retailer-dependent	High brand recognition	Pharmacy-dependent
Patent leverage	Limited	Limited for mature formulations	Limited
Main advantage	Price and availability	Recognition and marketing	Price

Rexall can compete effectively if it maintains consistent quality and availability while offering a lower retail price. A differentiated excipient platform is most valuable when it supports a visibly different dosage form or a measurable manufacturing advantage.

What manufacturing and IP barriers affect commercial expansion?

Manufacturing barriers are more important than active-ingredient patents. Key risks include supplier qualification, low-dose blend uniformity, dissolution control, packaging-line compatibility, and stability in retail distribution.

A scalable platform should establish:

• At least two qualified sources for critical excipients.
• Particle-size and moisture specifications for the active ingredient.
• Blend uniformity controls suited to the 2 mg dose.
• Dissolution testing sensitive to lubrication and hardness changes.
• Packaging compatibility studies.
• Accelerated and long-term stability data.
• Change-control procedures for excipient suppliers.
• Complaint trending for tablet defects and dosing concerns.

Trade-secret protection may cover blending order, granulation endpoint, coating parameters, compression settings, and packaging processes. These controls can protect cost and quality advantages even when patent protection is weak.

What are the most attractive commercial opportunities for Rexall Anti-Diarrheal?

The best near-term opportunity is a cost-optimized, robust immediate-release tablet supported by retailer-specific pack sizes and strong supply performance. The best medium-term opportunity is a premium convenience format, particularly a softgel or taste-masked orally disintegrating product.

Potential commercial extensions include:

1. Single-dose travel packs.
2. Large-count family packs.
3. Unit-dose blister packaging.
4. Private-label club-store formats.
5. E-commerce multipacks.
6. Adult gastrointestinal kits combining loperamide with oral rehydration products.
7. Products designed for consumers who have difficulty swallowing tablets.
8. Regional formulations adapted to excipient preferences or labeling requirements.

Combination products require careful regulatory review. Loperamide should not be combined with ingredients that create misleading claims, dosing confusion, or inappropriate treatment positioning.

Key Takeaways

• Rexall Anti-Diarrheal is generally a loperamide hydrochloride 2 mg OTC product.
• The active ingredient has little practical exclusivity value.
• Conventional tablet excipients should prioritize low cost, blend uniformity, rapid disintegration, and stable shelf life.
• Croscarmellose sodium, crospovidone, microcrystalline cellulose, dibasic calcium phosphate, povidone, colloidal silicon dioxide, and magnesium stearate are representative excipient choices.
• The strongest commercial differentiation is likely to come from softgels, chewables, orally disintegrating tablets, packaging, and private-label economics.
• Formulation patents may provide limited protection, but manufacturing know-how and supply reliability are more commercially important.
• Generic entry and private-label substitution risk are high.
• The preferred development strategy is a low-cost standard tablet followed by a selectively premium convenience format.

FAQs About Rexall Anti-Diarrheal Excipients and Commercial Strategy

What is the most important excipient for Rexall Anti-Diarrheal tablet performance?

The disintegrant is one of the most important excipient classes because rapid tablet breakup supports immediate-release performance. The amount and grade of croscarmellose sodium or crospovidone must be balanced against tablet hardness, lubricant level, and compression force.

Can Rexall Anti-Diarrheal be reformulated as a lactose-free product?

Yes. A lactose-free platform can use microcrystalline cellulose, dibasic calcium phosphate, mannitol, starch, or other suitable fillers. The replacement must preserve compressibility, dissolution, stability, and content uniformity.

Is there a strong patent opportunity for a loperamide excipient formulation?

A conventional tablet is unlikely to support strong patent protection. A patent opportunity is more credible for a technically distinct system involving taste masking, rapid disintegration, multiparticulates, abuse deterrence, or a specific manufacturing process.

Would a softgel provide a meaningful commercial advantage?

A softgel can improve swallowability and create a premium product position. Its commercial value depends on whether the price premium covers higher shell, fill, packaging, and manufacturing costs.

Is biosimilar risk relevant to Rexall Anti-Diarrheal?

No. Loperamide is a small-molecule active ingredient, not a biologic. Biosimilar regulation does not apply. Competitive risk comes from generic loperamide, private-label products, contract manufacturers, and retailer substitution.

References

1. U.S. Food and Drug Administration. (2024). Antidiarrheal drug products for over-the-counter human use. FDA Over-the-Counter Monograph System.

2. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (2018). FDA warns about serious heart problems with high doses of the anti-diarrheal medicine loperamide (Imodium), including doses higher than recommended. https://www.fda.gov

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda.